Payment overview · 2025
General Payments
$1,881.03
126 reported records · 15 companies
Healthcare provider profile · identity verified
Gerald Theodore Rosenberg, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · SAN ANTONIO, TX · NPI 1649249624
Verified facts
What the public records show
CMS Open Payments records show Gerald Theodore Rosenberg, M.D. received $1,881.03 in general payments during 2025 across 126 reported records.
Novartis Pharmaceuticals Corporation accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Prolia, Rinvoq, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $328.34 | 17.5% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $298.04 | 15.8% | 20 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $289.13 | 15.4% | 26 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $285.61 | 15.2% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $263.71 | 14.0% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $206.35 | 11.0% | 20 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $57.98 | 3.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.41 | 2.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.99 | 1.2% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.37 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.38 | 0.8% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $14.86 | 0.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.17 | 0.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $14.04 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.65 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,881.03 | 126 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $312.15 | 13 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $298.04 | 20 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $289.13 | 26 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $247.22 | 8 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $160.70 | 15 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $135.15 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $124.53 | 8 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $57.98 | 4 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $54.53 | 6 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $52.04 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.04 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $45.65 | 5 | 2025 |
Source payment records
|
|||||
| STEALTHSTATION S8 PLATFORM Normalized: stealthstation s8 platform |
Device | Medtronic, Inc. | $37.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.10 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $24.51 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $9.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENBREL enbrel |
2025 | Enbrel | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 116 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
116 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1158 | 188 |
| Prednisone | Prednisone | 616 | 166 |
| Alprazolam | Alprazolam | 539 | 82 |
| Gabapentin | Gabapentin | 531 | 119 |
| Tramadol Hcl | Tramadol Hcl | 403 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 369 | 76 |
| Celecoxib | Celecoxib | 319 | 74 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 310 | 73 |
| Pregabalin | Pregabalin | 270 | 57 |
| Methylprednisolone | Methylprednisolone | 240 | 106 |
| Methotrexate | Methotrexate Sodium | 218 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 215 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 203 | 46 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 200 | 46 |
| Meloxicam | Meloxicam | 195 | 55 |
| Trazodone Hcl | Trazodone Hcl | 172 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 37 |
| Morphine Sulfate Er | Morphine Sulfate | 162 | 23 |
| Hydromorphone Hcl | Hydromorphone Hcl | 140 | 20 |
| Carisoprodol | Carisoprodol | 139 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 39 |
| Clonazepam | Clonazepam | 119 | 21 |
| Rinvoq | Upadacitinib | 116 | 15 |
| Sertraline Hcl | Sertraline Hcl | 105 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 24 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Temazepam | Temazepam | 93 | 16 |
| Ibuprofen | Ibuprofen | 82 | 22 |
| Alendronate Sodium | Alendronate Sodium | 79 | 25 |
| Morphine Sulfate | Morphine Sulfate | 77 | 12 |
| Allopurinol | Allopurinol | 74 | 21 |
| Omeprazole | Omeprazole | 73 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 15 |
| Losartan Potassium | Losartan Potassium | 69 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 21 |
| Topiramate | Topiramate | 65 | 12 |
| Leflunomide | Leflunomide | 63 | 20 |
| Promethazine Hcl | Promethazine Hcl | 63 | 14 |
| Famotidine | Famotidine | 62 | 23 |
| Bupropion Xl | Bupropion Hcl | 61 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 25 |
| Fentanyl | Fentanyl | 58 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | 12 |
| Lidocaine | Lidocaine | 56 | 14 |
| Methadone Hcl | Methadone Hcl | 54 | suppressed |
| Methocarbamol | Methocarbamol | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 14 |
| Nabumetone | Nabumetone | 52 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Humira(Cf) Pen | Adalimumab | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | 13 |
| Furosemide | Furosemide | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 48 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 17 |
| Movantik | Naloxegol Oxalate | 46 | 15 |
| Triazolam | Triazolam | 46 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Diazepam | Diazepam | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 43 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Eszopiclone | Eszopiclone | 41 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 38 | suppressed |
| Etodolac | Etodolac | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 26 |
| Baclofen | Baclofen | 37 | 11 |
| Naproxen | Naproxen | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Enbrel Sureclick | Etanercept | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Folic Acid | Folic Acid | 34 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 33 | suppressed |
| Zaleplon | Zaleplon | 33 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Lisinopril | Lisinopril | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Azathioprine | Azathioprine | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Tymlos | Abaloparatide | 23 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Enbrel | Etanercept | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Lasix | Furosemide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,881.03 · 126 records | Novartis Pharmaceuticals Corporation | BENLYSTA, Bimzelx, COSENTYX, ENBREL, EVENITY, Gamunex-C, HADLIMA, KRYSTEXXA, LUPKYNIS, OTEZLA, PROLIA, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, STEALTHSTATION S8 PLATFORM, Senza, TAVNEOS, TERIPARATIDE, TREMFYA, Tymlos, UPLIZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enbrel play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error